Will Weight-Loss Drugs Spike Medicare Costs?: The Kiplinger Letter
Even a small portion of Medicare patients on weight-loss drugs like Wegovy could have a big effect.
To help you understand what is going on in the healthcare industry and what we expect to happen in the future, our highly-experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest...
The cost of new weight loss drugs will soon complicate federal finances. Though not covered by Medicare today, the odds are good that will change in the coming years. The estimated cost is $14 billion to $27 billion if a small portion of Medicare patients take treatments such as Novo Nordisk’s Wegovy for obesity. The estimate is on par with Aduhelm, the recently approved Alzheimer’s drug, which also threatens to seriously hike Medicare spending on prescription drugs.
Drugs for weight loss are barred from Medicare coverage, via a 2006 law that prohibits obesity treatments, but many lawmakers want to change that. Medicare Part D often does cover Novo Nordisk’s Ozempic for diabetes, though, which works in a similar manner as Wegovy and spurs substantial weight loss. The feds are mulling what the drugs will mean for Medicare solvency.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
However, there is a huge potential for major cost savings — eventually. One early estimate by University of California, San Francisco researchers in a white paper: Savings of $175 billion to $245 billion in the first 10 years alone by reducing obesity rates and other related health conditions. The higher figure assumes private insurers offer coverage and that obesity among Medicare patients would fall drastically. Still, there’s lots of uncertainty and any savings will take years to appear.
Alongside the rapid rise of new breakthrough weight loss drugs, expect rising demand for digital health services that help with weight loss, a seemingly paradoxical trend. If the drugs work, why will folks need these services, such as programs from 60-year-old Weight Watchers?
A few reasons: Many patients will want to monitor their health, nutrition and fitness with personalized programs from experts, such as dieticians. Employers will require enrollment in programs, including supervised diets and fitness plans. Patients will need continued support to stay on the drugs (if they stop taking them, they are likely to regain the weight).
Among the digital health companies vying for customers using the drugs: Every Health, Ro, Hims & Hers, Calibrate, Form Health, Amazon’s One Medical and Teladoc. Venture capitalists are pouring tens of millions of dollars into the industry.
Meanwhile, WeightWatchers recently spent $132 million to buy start-up Sequence, which pairs patients with prescribing doctors, a big bet on this fast-growing market. The drug can be prescribed through a virtual visit or by submitting an online form, prompting a concern among experts that prescriptions are being given out too easily.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
To continue reading this article
please register for free
This is different from signing in to your print subscription
Why am I seeing this? Find out more here
John Miley is a Senior Associate Editor at The Kiplinger Letter. He mainly covers technology, telecom and education, but will jump on other important business topics as needed. In his role, he provides timely forecasts about emerging technologies, business trends and government regulations. He also edits stories for the weekly publication and has written and edited e-mail newsletters.
He joined Kiplinger in August 2010 as a reporter for Kiplinger's Personal Finance magazine, where he wrote stories, fact-checked articles and researched investing data. After two years at the magazine, he moved to the Letter, where he has been for the last decade. He holds a BA from Bates College and a master’s degree in magazine journalism from Northwestern University, where he specialized in business reporting. An avid runner and a former decathlete, he has written about fitness and competed in triathlons.
-
How to Help Your Kids Without Ruining Your Retirement
Here are some general considerations to ensure the gift of assets to your kids will not negatively affect your financial future.
By Mario Hernandez Published
-
AI to Power the Next Generation of Robots
The Kiplinger Letter There's increasing buzz that the tech behind ChatGPT will make future industrial and humanoid robots far more capable.
By John Miley Published
-
Tax Tips for Transferring Excess 529 Plan Funds to Roth IRAs: The Tax Letter
The Tax Letter 529 plans can help blunt the cost of paying for college. But if you want to use leftover funds there are some tax tips to bear in mind.
By Joy Taylor Published
-
When's the Best Time to Buy a Domestic Flight? The Kiplinger Letter
The Kiplinger Letter A new study by CheapAir.com has crunched the numbers.
By Sean Lengell Published
-
Woes Continue for Banking Sector: The Kiplinger Letter
The Kiplinger Letter Regional bank stocks were hammered recently after news of New York Community Bank’s big fourth-quarter loss.
By Rodrigo Sermeño Published
-
How to Report QCDs on Your Tax Return: The Tax Letter
The Tax Letter Qualified charitable distributions, otherwise known as QCDs, can be tricky when it comes to tax reporting. We've got some pointers to help with filing.
By Joy Taylor Published
-
What to Know Before Splitting 401(k) Assets in a Divorce: The Tax Letter
The Tax Letter Splitting 401(k) assets in a divorce can lead to unintended tax consequences, there are ways to avoid financial penalties.
By Joy Taylor Published
-
Anxious Flyers Take Note: The Kiplinger Letter
The Kiplinger Letter Whether it's the routes to avoid that have the most turbulence or the safest airline, we've got you covered.
By Sean Lengell Published
-
The Auto Industry Outlook for 2024
The Kiplinger Letter Here's what to expect in the auto industry this year. If you’re in the market for a car it won’t be quite as daunting as it was during the pandemic and after.
By David Payne Published
-
Two More Travel Trends for 2024: The Kiplinger Letter
The Kiplinger Letter As the world gets moving again, two more travel trends to consider: Solo cruising and airline passengers with loaded guns.
By Sean Lengell Published